G1 Therapeutics buy Needham & Company LLC
Summary
This prediction is currently active. With a performance of 53.97% the BUY prediction by Needham___Company_LL is a big success. This prediction currently runs until 01.05.25. The prediction end date can be changed by Needham___Company_LL at any time. Needham___Company_LL has 50% into this predictionG1 Therapeutics is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer. Their lead product candidate, Trilaciclib, is designed to improve the outcomes of chemotherapy by preserving hematopoietic stem cells and immune system function. G1 Therapeutics is also developing therapeutics for lung cancer, glioblastoma multiforme, and other solid tumors. The company went public in May 2017 and is listed on the NASDAQ exchange under the symbol GTHX.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
G1 Therapeutics | 0.235% | 0.235% |
iShares Core DAX® | 1.560% | 4.721% |
iShares Nasdaq 100 | 0.517% | 1.171% |
iShares Nikkei 225® | 1.730% | 6.073% |
iShares S&P 500 | 1.482% | 1.218% |
Comments by Needham___Company_LL for this prediction
In the thread G1 Therapeutics diskutieren